NCT00206388View on ClinicalTrials.gov

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

May 31, 2013

Conditions
NEUROBLASTOMA
Interventions
DRUG

Zolendric acid

IV, 2mg/m2/dose on day 0

DRUG

Cyclophosphamide

fixed dose of 25mg/m2/dose days 0-27

Trial Locations (8)

19104

Children's Hospital of Philadelphia, Philadelphia

45229

Cincinnati Children's Hospital, Cincinnati

46202

Indiana University-Riley Children's Hospital, Indianapolis

53792

University of Wisconsin Medical Center, Madison

77030

Texas Children's Cancer Center, Houston

90027

Children's Hospital Los Angeles, Los Angeles

94143

USCF School of Medicine, San Francisco

94305

Lucille Salter Packer Children's Hospital, Stanford

All Listed Sponsors
collaborator

New Approaches to Neuroblastoma Therapy Consortium

OTHER

lead

Baylor College of Medicine

OTHER

NCT00206388 - Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement | Biotech Hunter | Biotech Hunter